BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac

  • Pfizer Inc PFE and BioNTech SE BNTX have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. CVAC.
  • CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology.
  • Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech.
  • It did not rule out further legal action against BioNTech's partner Pfizer.
  • BioNTech said that CureVac's U.S. patents, which BioNTech claims not to violate, were equivalent to German patents invoked by CureVac in the German court case, Reuters reported.
  • CureVac said that it was aware of BioNTech's legal action but had not yet been formally served.
  • "We will review the matter legally in detail and represent our position accordingly," it added.
  • Price Action: CVAC shares are down 0.37% at $13.42, and BNTX stock is down 1.52% at $159.91 during the market session on the last check Tuesday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareLegalGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!